Ambrx Biopharma American Stock Cash And Equivalents
| AMAMDelisted Stock | USD 15.73 0.71 4.73% |
Ambrx Biopharma American fundamentals help investors to digest information that contributes to Ambrx Biopharma's financial success or failures. It also enables traders to predict the movement of Ambrx Stock. The fundamental analysis module provides a way to measure Ambrx Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ambrx Biopharma stock.
Ambrx |
Ambrx Biopharma American Company Cash And Equivalents Analysis
Ambrx Biopharma's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Ambrx Biopharma Cash And Equivalents | 110.89 M |
Most of Ambrx Biopharma's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ambrx Biopharma American is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Ambrx Biopharma American has 110.89 M in Cash And Equivalents. This is 86.49% lower than that of the Biotechnology sector and 75.2% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 95.9% higher than that of the company.
Ambrx Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ambrx Biopharma's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics of similar companies.Ambrx Biopharma is currently under evaluation in cash and equivalents category among its peers.
Ambrx Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (483.51) % | |||
| Current Valuation | 1.56 B | |||
| Shares Outstanding | 63.29 M | |||
| Shares Owned By Insiders | 2.09 % | |||
| Shares Owned By Institutions | 97.91 % | |||
| Number Of Shares Shorted | 1.16 M | |||
| Price To Earning | 0.19 X | |||
| Price To Book | 7.31 X | |||
| Price To Sales | 432.96 X | |||
| Revenue | 4.09 M | |||
| Gross Profit | 7.4 M | |||
| EBITDA | (61.75 M) | |||
| Net Income | (67.06 M) | |||
| Cash And Equivalents | 110.89 M | |||
| Cash Per Share | 2.87 X | |||
| Total Debt | 11.98 M | |||
| Debt To Equity | 0.09 % | |||
| Current Ratio | 4.70 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (57.7 M) | |||
| Short Ratio | 1.21 X | |||
| Earnings Per Share | 0.42 X | |||
| Price To Earnings To Growth | (0.15) X | |||
| Target Price | 28.5 | |||
| Number Of Employees | 87 | |||
| Beta | -2.36 | |||
| Market Capitalization | 1.77 B | |||
| Total Asset | 146.98 M | |||
| Retained Earnings | (291.63 M) | |||
| Working Capital | 73.92 M | |||
| Z Score | 85.23 | |||
| Net Asset | 146.98 M |
About Ambrx Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ambrx Biopharma American's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ambrx Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ambrx Biopharma American based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |